Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US Midterms: Industry Loses Some Supporters In Congress, But Retains Many

Executive Summary

With most of the Nov. 6 election tally completed, it’s clear there will be many new faces for the device industry to engage with in the halls of Congress, but the sector still appears to have a significant group of supporters on Capitol Hill. Also, several medtech-relevant measures were on the ballot.

Advertisement

Related Content

3 Big Medtech Takeaways From US Midterms
3 Big Medtech Takeaways From US Midterms
Twenty-Four Congressional Midterm Races To Watch In US Medtech-Heavy Regions
Medtech Firms Focus Campaign Dollars On Device Bill Proponents, Excise Tax Opponents In 2018
Device Industry Champion Erik Paulsen In Tough Election Fight To Retain House Seat
10 Senate Dems Line Up On Paper Behind Device Tax Repeal
Medtech's Unfinished Business For Congress In 2018: What's Ahead
Draft Bill Aims To Clarify FDA Regulation Of Mobile Medical Apps

Topics

Advertisement
UsernamePublicRestriction

Register

MT124218

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel